David Kerins

  • You are here:

David Kerins – APC Faculty


Contact details: E-mail: d.kerins@ucc.ie



1981                       BSc Physiology, University College Cork

1984                       MB, BAO, BCh, University College Cork

1994                       MD, University College Cork

Career profile:

Present position:  Associate Professor of Therapeutics,  Department of Pharmacology and Therapeutics, UCC Consultant Physician and Cardiologist, Mercy University Hospital

Previous positions:

1993-2001                            Assistant Professor of Medicine, Vanderbilt University, Nashville, TN

1993-2003                            Staff Physician,     Nashville VA Medical Center, Nashville, TN

1993-2003                            Director of Echocardiography Laboratory, Nashville VA Medical Center,

1999-2003                            Chief, Cardiology Section, Nashville VA Medical Center, Nashville, TN

2003-2004                            Consultant Cardiologist and Physician, Wexford General Hospital, Wexford,

2001-2006                            Associate Professor of Medicine,     Vanderbilt University. Nashville, TN

2007-2010                            Dean Medical School, UCC

2008-2010                            Vice Head, College of Medicine and Health, UCC

Research interests:

Role of platelet activation in cardiovascular disease

The interactions of the renin-angiotensin aldosterone and fibrinolytic systems

Vascular Biology

Non-invasive cardiac imaging including the use of Echocardiography, Cardiac Magnetic Resonance Imaging and Coronary CT Angiography


College Entrance Scholarship to University College Cork.

Medical Research Council of Ireland Scholarship.

Dr. Henry Hutchinson Stewart Prize in Pharmacology,  National University of Ireland.

Ainsworth Scholarship of University College Cork.

Merck Sharp and Dohme International Fellowship in Clinical Pharmacology

Fellowship Award, Pharmaceutical Manufacturers Association Foundation.

Raymond Shanahan Memorial Prize in Cardiology, University College Cork.

Fellowship Award, Health Research Board of Ireland

New Investigator Award, Tennessee Affiliate, American Heart Association.

Cardiology Faculty Teaching Award, Division of Cardiovascular Medicine, Vanderbilt University.

Outstanding Lecturer Award, Department of Pharmacology, Vanderbilt University

Membership of relevant committees/editorial boards:

Fellow, American Heart Association,

Fellow, American College of Cardiology,

Fellow, American Society of Echocardiography.

Fellow, European Society of Cardiology

Member, Society of Cardiovascular Magnetic Resonance

Recent relevant publications:

Kerins D.M., Roy L., FitzGerald G.A., & Fitzgerald D.J. Platelet and vascular function during coronary thrombolysis with tissue-type plasminogen activator. Circulation 1989; 80: 1718-1725.

Kerins D.M., Shuh M., Kunitada S., FitzGerald G.A., & Fitzgerald D.J. A prostacyclin analog impairs the response to tissue-type plasminogen activator during coronary thrombolysis: Evidence for a pharmacokinetic interaction. Journal of Pharmacology and Experimental Therapeutics 1991; 257: 487-492.

Kerins D.M., & FitzGerald G.A. The current role of platelet-active drugs in ischaemic heart disease. Drugs 1991; 41: 665-671.

Velasco C.E., Kerins D.M., Howe D., Fitzgerald D.J., & Forman M.B. Effects of intravenous adenosine on tissue type plasminogen activator pharmacokinetics in humans. Coronary Artery Disease 1991; 2: 1069-1075.

Kerins D.M., Roy L., Kunitada S., Adedoyin A., FitzGerald G.A., & Fitzgerald D.J. The pharmacokinetics of tissue-type plasminogen activator during acute myocardial infarction in man: effect of a prostacyclin analogue. Circulation 1992; 85: 526-532.

Charman W.N., Kerins D.M., & FitzGerald G.A. Aspirin: Pharmacokinetics and pharmacodynamic effects on platelets and vascular function. In: Aspirin and other salicylates. Vane, J.R. & Botting, R. (eds) Chapman & Hall, London 1992; 74-107.

Kerins D.M., Hao Q., Vaughan D.E. Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV. Journal of Clinical Investigation 1995; 96: 2515-2520.

Kemp W.E., Kerins D.M., Shyr Y., Byrd III, B.F. Optimal Albunex dosing for enhancement of Doppler tricuspid regurgitation. American Journal of Cardiology. 1997; 79:232-234.

Darbar D., Gillespie N., Choy A.-M.J., Lang C.C., Pringle S.D., Pringle T.H., Kerins D.M., McNeill G.P., Struthers A.D.  Diagnosing left ventricular dysfunction after myocardial infarction: the Dundee algorithm. Quarterly Journal of Medicine 1997; 90: 677-683.

Tang H*., Kerins D.M.*, Hao Q., Inagami T., Vaughan, D.E. Signal transduction of the urokinase-type plasminogen activator receptor: Enhancement of tyrosine phosphorylation of focal adhesion proteins and activation of MAP kinase. Journal of Biological Chemistry 1998; 273: 18268-18272 (* Co-first authors).

Roselli, H.T, Su M., Washington, K., Kerins D.M., Vaughan D.E, Russell W.E. Liver regeneration is transiently impaired in urokinase deficient mice. American Journal of Physiology 1998; 275: G1472-1479.

Darbar D., Cherry C.J., Kerins D.M. QT Dispersion is reduced after aortic valve replacement in patients with aortic stenosis.  Heart 1999; 82: 15-18.

Kerins D.M., Robertson R.M., Robertson D. Drugs used for the treatment of myocardial ischemia. Goodman and Gilman’s. The Pharmacological Basis of Therapeutics, 10th Edition, 2001; 843-70.

Kerins D.M., Koury M.J., Capdevilla A., Rama S., Wagner C. Plasma S-adenosylhomocysteine is a more sensitive marker of cardiovascular disease than plasma homocysteine. American Journal of Clinical Nutrition 2001:; 74:723-9.

Wagner C., Stone W.J., Koury M.J., Dupont W.D., Kerins D.M., S-adenosylhomocysteine is a more sensitive indicator of renal insufficiency than homocysteine. Nutrition Research 2004; 24: 487–494

Doyle O.M., Korotchikova I, Lightbody G., Marnane W., Kerins D., Boylan G. Heart rate variability during sleep in healthy term newborns in the early postnatal period. Physiological Measurement 2009; 30:847-60

Phelan M. Kerins D. The potential role of milk-derived peptides in cardiovascular disease. Food Function 2011, 2:153-167.

Ledwidge M.T., Ryan F., Kerins, D.M., O’Connell, D., Cefali, G., Harmon S., Jones, M., Gilmer, J.F. In vivo impact of prodrug isosorbide-5-nicotinate-2-aspirinate on lipids and prostaglandin D2: Is this a new immediate-release therapeutic option for niacin?. Atherosclerosis 2012, 221:478-83.

Gao Y., O’Caoimh R., Healy L., Kerins D.M., Eustace J., Guyatt, G., Sammon D., Molloy D.W. Effects of centrally acting ACE inhibitors on the rate of cognitive decline in dementia. BMJ Open 2013;3:e002881. doi:10.1136/bmjopen-2013- 002881

Phelan, M., Khaldi, N., Shields, D.C., Kerins, D.M. Angiotensin converting enzyme and nitric oxide inhibitory activities of novel milk derived peptides. International Dairy Journal. 2014, 35:38-42.

O’Caoimh R., Healy L., Gao Y., Svendrovski A., Kerins D.M., Eustace J., Kehoe P.G., Guyatt G., Molloy D.W. Effects of centrally acting angiotensin enzyme inhibitors on functional decline in patients with Alzheimer’s disease. Journal of Alzheimers Disease. 2014, 40:595-603 DOI:10.3233/JAD-131694

Clarke S.F., Murphy E.F., O’Sullivan O., Lucey A.J., Humphreys M., Hogan A., Hayes P., O’Reilly M., Jeffery I.B., Wood-Martin R., Kerins D.M., Quigley E., Ross R.P., O’Toole P.W., Molloy M.P., Falvey E., Shanahan F., Cotter P.D. Exercise and associated dietary extremes impact on gut microbial diversity. Gut. Gut, 2014, 63:1913-20 doi:10.1136/gutjnl-2013-306541